Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic adjuvant therapy for node-negative breast cancer.

A D Ginsburg1, D J Perrault, K I Pritchard

  • 1Kingston Regional Cancer Centre, Ont.

CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.

Breast cancer research and treatment·2020
Same author

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2019
Same author

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.

Breast cancer research and treatment·2018
Same author

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.

Breast cancer research and treatment·2018
Same author

Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.

Breast cancer research and treatment·2017
Same author

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.

European journal of cancer (Oxford, England : 1990)·2017

Systemic adjuvant therapy for node-negative breast cancer shows modest disease-free survival benefits but not overall survival. Routine use is not justified; identify high-risk patients for potential benefit.

Area of Science:

  • Oncology
  • Breast Cancer Research
  • Clinical Therapeutics

Background:

  • Recent US National Cancer Institute (NCI) advice prompts re-evaluation of systemic adjuvant therapy for node-negative breast cancer.
  • Existing literature indicates a complex benefit profile for adjuvant therapy in this patient group.

Purpose of the Study:

  • To review the literature on systemic adjuvant therapy for node-negative breast cancer in light of NCI recommendations.
  • To assess the survival advantages and potential drawbacks of such therapies.

Main Methods:

  • Literature review of studies investigating systemic adjuvant therapy for node-negative breast cancer.
  • Analysis of reported disease-free survival (DFS) and overall survival (OS) data.

Main Results:

Related Experiment Videos

  • Several studies demonstrate a disease-free survival advantage for patients receiving adjuvant therapy.
  • No significant overall survival advantage has been consistently observed.
  • Observed benefits are modest and may be outweighed by therapy costs and toxic effects.

Conclusions:

  • Routine use of systemic adjuvant therapy for node-negative breast cancer is not currently justified.
  • Further research is needed to identify patient subgroups (high-risk vs. low-risk) who may truly benefit from adjuvant therapy.
  • Personalized treatment strategies are essential to optimize outcomes and minimize adverse effects.